Description
Created On: 2020-07-15
Record Count: 5
Primary Industries
- Drugs
- Disease
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203504
IPSCIO Record ID: 279299
For the License of proprietary rights, Licensor grants a co-exclusive, with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof, Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.
The research license portion is non-exclusive.
Licensor will screen at least five million (5,000,000) compounds contained in the Licensor NeoMorph Screening Library against each Shared Target.
Licensee will provide at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.
Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.
Licensee is interested in identifying potential pharmaceutical products for the treatment of human immunodeficiency virus (HIV) and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.
IPSCIO Record ID: 281539
Licensor grants a co-exclusive with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof and Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.
The research license portion is non-exclusive.
Licensee will screen at least five million (5,000,000) compounds contained in the Licensee NeoMorph Screening Library against each Shared Target.
Licensor will provide Licensee with at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.
Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.
IPSCIO Record ID: 289184
The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.
Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.
7,250,421 – Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.